Appian Labs Entered Into Development, Commercial License With Capsugel

Appian Labs has entered an exclusive development and commercial license agreement for AppiForm Modular Release System with Capsugel. The agreement provides for Capsugel to utilise the AppiForm Modular Release System for customisable drug delivery profiles.

Under the terms of the agreement, Capsugel will have exclusive rights to the AppiForm Modular Release System technology that enables custommatching of desired release kinetics. The AppiForm platform formulations can be used to develop oral dosage forms with release profiles that include periods of delayed action, controlled decreasing rate or even increasing rate of release as well as zero order delivery. The design of the AppiForm system allows for release of several drugs or beneficial agents in sequential mode at constant or decreasing rates.

Brian Windsor, president of Appian, said: “We are extremely pleased to partner with Capsugel in exclusive development. The types of release profiles afforded by the AppiForm system are increasingly in demand globally. As both a leader and innovator in pharmaceutical products and services, Capsugel is a perfect fit for developing and launching the AppiForm technology.”

Keith Hutchison, vice president of research and development for Capsugel, said: “This agreement with Appian Labs supports our strategy to offer a wide range of oral dosage form solutions to our healthcare customers around the world. The drug delivery performance of the AppiForm technology is impressive. It will allow our customers to achieve customized release profiles for their API’s, and at the same time to bring new products to market by taking advantage of Capsugel’s manufacturing know-how.”

Agreement with Capsugel for the AppiForm Modular Release System, in addition to capsule products, Capsugel offers a comprehensive product and service array for drug formulations in liquid form as part of its Licaps drug delivery system.